Recent Quotes (30 days)

You have no recent quotes
chg | %

Alchemia Limited  

(Public, ASX:ACL)   Watch this stock  
Find more results for ASX: ACL
-0.0010 (-7.69%)
Feb 23 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.01 - 0.01
52 week 0.01 - 0.03
Open 0.01
Vol / Avg. 1.68M/1.90M
Mkt cap 3.90M
P/E     -
Div/yield     -
EPS 0.00
Shares 324.72M
Beta     -
Inst. own     -
Feb 20, 2018
Half Year 2018 Alchemia Ltd Earnings Release
Jan 25, 2018
Q2 2018 Alchemia Ltd Cashflow Reports
Nov 28, 2017
Alchemia Ltd Annual Shareholders Meeting

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -4229.84% -5281.43%
Operating margin -4229.84% -5499.71%
EBITD margin - -5499.71%
Return on average assets -17.08% -20.70%
Return on average equity -17.61% -21.90%
Employees 29 -
CDP Score - -


3 Hi-Tech Ct, L 4 100 Albert Rd
+61-3-96927222 (Phone)
+61-3-90779233 (Fax)

Website links


Alchemia Limited is a biotechnology company. The Company is engaged in the sale of its around the world intellectual property rights to Fondaparinum sodium, a generic anti-coagulant drug to Dr Reddy's Laboratories; closure of clinical trial activities, and review of new opportunities. The Company's segments include Fondaparinux and HyACT. The Company is engaged in the commercialization and improvements of its generic Fondaparinux product. The Company's HyACT is a platform technology that targets cancer drugs directly to tumors, designed to increase effectiveness against tumors without increasing toxicity. Its lead product candidate, HA-Irinotecan is used in the treatment of metastatic colorectal cancer (mCRC) and is in Phase III clinical trials. Its subsidiary, Alchemia Oncology Inc. is engaged in commercializing its HyACT and VAST platforms, including HA-Irinotecan. The Company's Audeo Oncology, Inc is engaged in the development and commercialization of the HyACT platform.

Officers and directors

Melanie Jaye Leydin Chief Financial Officer, Company Secretary
Tracey J. Brown Ph.D. Chief Scientific Officer, Vice President - Oncology
Michael L. West Ph.D. Vice President - Intellectual Property and Technology Transfer
Goslik Schepers Vice President - Business Development
Imran Ahamed Group Financial Controller
Wim Meutermans Ph.D. Chief Scientific Officer - Audeo Discovery
Simon Gennari Non-Executive Chairman of the Board
Darren Rael Book Non-Executive Director
David Lamm Non-Executive Director